Alpha-9 Oncology
Alison Fleming is the current Chief Operating Officer at Alpha-9 Theranostics Inc. Previously, Alison held the position of Chief Technical Officer at Collegium Pharmaceutical, Inc. where Alison played a crucial role in the development and commercial manufacturing of various pharmaceutical products. With a background in Chemical and Biomolecular Engineering, Alison has a strong foundation in product research and development, project management, and regulatory efforts. Alison has contributed significantly to the growth and success of pharmaceutical companies throughout their career.
Alpha-9 Oncology
Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.